Evidence map›Paper›PMID 36372731›Full record

Trial reportEBioMedicine2022

Ingestible sensor system for measuring, monitoring and enhancing adherence to antiretroviral therapy: An open-label, usual care-controlled, randomised trial.

Honghu Liu, Yan Wang, Yilan Huang, Di Xiong, Jie Shen, Lisa Siqueiros, Veenu Bala, George M Savage, Mario Guerrero, Katya Corado and 3 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in EBioMedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Application progress of latent class growth models in dynamic prevention and control strategies for acquired immunodeficiency syndrome.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024
    Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Honghu LiuSection of Public and Population Health, School of Dentistry, University of California, Los Angeles (UCLA), Los Angeles, CA, USA; Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA; Department of Biostatistics, Fielding School of Public Health, UCLA, Los Angeles, CA, USA. Electronic address: hhliu@mednet.ucla.edu.
Yan WangSection of Public and Population Health, School of Dentistry, University of California, Los Angeles (UCLA), Los Angeles, CA, USA; Division of Infectious Diseases, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
Yilan HuangDepartment of Biostatistics, Fielding School of Public Health, UCLA, Los Angeles, CA, USA.
Di XiongDepartment of Biostatistics, Fielding School of Public Health, UCLA, Los Angeles, CA, USA.
Jie ShenSection of Public and Population Health, School of Dentistry, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.
Lisa SiqueirosDepartment of Medicine, Division of HIV Medicine, Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.
Veenu BalaCenter for Drug Discovery, University of Nebraska Medical Center, Omaha, NE, USA; Jounce Therapeutics, Inc. Cambridge, MA, USA.
George M SavageProteus Digital Health, Redwood City, CA, USA; Windmill Partners LLC, Portola Valley, CA, USA.
Mario GuerreroDepartment of Medicine, Division of HIV Medicine, Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.
Katya CoradoDepartment of Medicine, Division of HIV Medicine, Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.
Marc I RosenDepartment of Psychiatry, School of Medicine, Yale University, New Haven, CT, USA; VA Connecticut Healthcare System, West Haven, CT, USA.
Courtney V FletcherCenter for Drug Discovery, University of Nebraska Medical Center, Omaha, NE, USA.
Eric S DaarDepartment of Medicine, Division of HIV Medicine, Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Postdoctoral Training in Global AIDS Prevention ResearchT32MH080634 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JESSE LAWTON CLARK, Pamina Mae Gorbach · 2007 to 2026
$6.4M
Measuring and Monitoring Adherence to ART with Pill Ingestion Sensor SystemR01MH110056 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DAAR, ERIC S, LIU, HONGHU · 2015 to 2019
$4.0M
NCATS NIH HHS UL1 TR001863NIMH NIH HHS R01 MH110056NIMH NIH HHS T32 MH080634
6 · The paper itself

Abstract

backgroundCo-encapsulated antiretrovirals (ARVs) with ingestible sensor (IS) has the capacity to monitor adherence in real-time using a sensor patch, a mobile device, and supporting software. We evaluated the acceptability, effectiveness, and sustainability of the IS system with real-time text reminders.

methodsParticipants were recruited from HIV clinics in Los Angeles and were randomised 1:1 to IS or usual care (UC) group. Adherence to ARVs (primary outcome) was measured by IS system (IS group only), plasma ARV concentration, and self-report. IS-measured adherence was clustered by group-based trajectory model and was validated by ARV concentration summarized by integrated pharmacokinetic adherence measure (IPAM) score. HIV RNA viral load (VL) was compared between IS and UC group.

findingsA total of 112 (IS = 54, UC = 58) participants who completed baseline with at least one follow-up data collection were included in analyses. Overall satisfaction rate for the IS system was >90%. The IPAM score was higher (0.018, 95% CI: -0.098-0.134, p = 0.75) and VL decayed faster (-0.020, 95% CI: -0.042-0.002, p = 0.08) in the IS group compared with the UC group. The ingestible sensor system was well tolerated by study participants.

interpretationThe IS system was well accepted by participants and its use was associated with improved adherence and lower HIV RNA VL. The findings provide a potentially effective strategy for improving adherence.

fundingThis work was supported by grant R01-MH110056 from the National Institute of Mental Health (NIMH)/National Institutes of Health (NIH). Y. Wang was in part supported by the NIMH/NIH award T32MH080634. E. Daar was in part supported by the National Center for Advancing Translational Sciences through UCLACTSI Grant UL1TR001881. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Indexed as

HIV InfectionsMedication AdherenceAnti-Retroviral AgentsHumansRNAViral LoadAnti-Retroviral AgentsRNAAdherenceHIVIngestible sensorPharmacokineticViral load

Identifiers

PMID36372731
PMCPMC9782816

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.